Back to results
US 7,923,544 B2Granted
Biomarkers for inflammatory bowel disease and irritable bowel syndrome
AssigneeExagen Diagnostics, Inc.
InventorsCole Harris, John Alsobrook
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions and their use in diagnosing and/or distinguishing inflammatory bowel disease and irritable bowel syndrome.
Claims15
A biomarker consisting of between 7 and 35 different nucleic acid probe sets, wherein:
- (a) a first probe set consisting of one or more nucleotide probes consisting of 15 or more contiguous nucleotides of SEQ ID NO:5 (UBE2G1), or a full complement thereof;
- (b) a second probe set consisting of one or more nucleotide probes consisting of 15 or more contiguous nucleotides of SEQ ID NO:6 (CALM3), or a full complement thereof;
- (c) a third probe set consisting of one or more nucleotide probes consisting of 15 or more contiguous nucleotides of SEQ ID NO:9 (HIST1H2BK), or a full complement thereof;
- (d) a fourth probe set consisting of one or more nucleotide probes consisting of 15 or more contiguous nucleotides of SEQ ID NO:10 (PPP2R5A), or a full complement thereof;
- (e) a fifth probe set consisting of one or more nucleotide probes consisting of 15 or more contiguous nucleotides of—SEQ ID NO:3 (BLCAP), or a full complement thereof;
- and
- (f) a sixth probe set and a seventh probe set consisting of one or more nucleotide probes consisting of 15 or more contiguous nucleotides of a nucleic acid selected from the group consisting of
- (i) SEQ ID NO:1 (RAP1A) and SEQ ID NO:7 (GPX1) or full complements thereof;
- (ii) SEQ ID NO:2 (RAP1A) and SEQ ID NO:7 (GPX1) or full complements thereof;
- (iii) SEQ ID NO:1 (RAP1A) and SEQ ID NO:8 (GPX1) or full complements thereof;
- and
- (iv) SEQ ID NO:2 (RAP1A) and SEQ ID NO:8 (GPX1) or full complements thereof;
- wherein each of the between 7 and 35 different probe sets consists of one or more probes of 15 or more contiguous nucleotides, or full complements thereof, of a different mRNA, and wherein each of the different probe sets is optionally detectably labeled.
10 more elements
A biomarker consisting of between 7 and 35 different nucleic acid primer pairs, including
- (a) a first primer pair, wherein each primer in the first primer pair consists of 15 or more contiguous nucleotides of SEQ ID NO:5 (UBE2G1), or a full complement thereof;
- (b) a second primer pair, wherein each primer in the second primer pair consists of 15 or more contiguous nucleotides of SEQ ID NO:6 (CALM3), or a full complement thereof;
- (c) a third primer pair, wherein each primer in the third primer pair consists of 15 or more contiguous nucleotides of SEQ ID NO:9 (HIST1H2BK), or a full complement thereof;
- (d) a fourth primer pair, wherein each primer in the fourth primer pair consists of 15 or more contiguous nucleotides of SEQ ID NO:10 (PPP2R5A), or a full complement thereof;
- (e) a fifth primer pair, wherein each primer in the fifth primer pair consists of 15 or more contiguous nucleotides of SEQ ID NO:3 (BLCAP), or a full complement thereof;
- and
- (f) a sixth primer pair and a seventh primer pair, wherein each primer in the sixth primer pair and the seventh primer pair consists of 15 or more contiguous nucleotides of a nucleic acid selected from the group consisting of
- (i) SEQ ID NO:1 (RAP1A) and SEQ ID NO:7 (GPX1) or full complements thereof;
- (ii) SEQ ID NO:2 (RAP1A) and SEQ ID NO:7 (GPX1) or full complements thereof;
- (iii) SEQ ID NO:1 (RAP1A) and SEQ ID NO:8 (GPX1) or full complements thereof;
- and
- (iv) SEQ ID NO:2 (RAP1A) and SEQ ID NO:8 (GPX1) or full complements thereof;
- wherein each of the between 7 and 35 different primer pairs consists of one or more primer pairs, wherein each primer consists of 15 or more contiguous nucleotides, or full complements thereof, for a different mRNA, and wherein each of the different primer pairs is optionally detectably labeled.
10 more elements
Dependencies are inferred from the claim text.